BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Indian pharma firm Venus Remedies gets marketing approval for cancer drugs in Uzbekistan, Palestine

February 23, 2023 | News

The marketing authorisations for three generic drugs signifying advances in cancer treatment to benefit patients

Indian pharmaceutical company Venus Remedies has received marketing authorisation for its generic cancer drugs from Uzbekistan and Palestine. Having over 800 marketing authorisations worldwide, the company is making big strides by now extending its footprint in Central Asia and Middle East with the marketing approval for Carboplatin in Uzbekistan and Docetaxel and Irinotecan in Palestine.

Uzbekistan and Palestine have limited access to quality medicines, and Venus Remedies is expected to launch these drugs in the two countries in the next financial year.

These marketing authorisations have further strengthened the company's commitment to providing cost-effective generic alternatives to expensive branded drugs and improving access to affordable medicines to cancer patients in need. With these marketing approvals, the three generic cancer drugs signifying advances in cancer treatment will considerably benefit thousands of patients as well as the broader healthcare community.

Venus Remedies is considered among the top-class manufacturers of oncological, carbapenem and cephalosporin injectable products. The company is contributing substantially in the oncology segment across the globe through its wide array of key products, which include Docetaxel, Paclitaxel, Gemcitabine, Oxaliplatin, Bortezomib and Pemetrexed.